Monday June 26th 2017

Archive for May, 2011

Medical tourism: Opportunity or problem?

Medical tourism: Opportunity or problem?

Two years ago, Brendan King turned to a medical-tourism company to help book his trip. The Campbell River man was on his way to Costa Rica to receive a controversial treatment for his multiple sclerosis. The “liberation” treatment isn’t offered in Canada, [Read More]

It’s decision time for voters

It’s decision time for voters

This was an open letter emailed to the EMC newspaper. Dear Editor: Dalton McGuinty, Tim Hudak, Andrea Horwath, tomorrow (hypothetically) will be a memorable day for you, because tomorrow, you will wake up seeing two of everything. You won’t be able to drive, and [Read More]

Liberation has helped yet another MS sufferer

Liberation has helped yet another MS sufferer

Miraculous is how Bev Downie sees the change in her daughter after receiving angioplasty, also known as liberation therapy, for multiple sclerosis in California recently. It was a journey of hope and Bev was brimming with emotion as she described, to the News on Tuesday, [Read More]

 Page 1 of 6  1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]